Fabry Disease and Amenable GLA Variants and Severe Renal Impairment or Endstage research hub

AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF MIGALASTAT HCL IN SUBJECTS WITH FABRY DISEASE AND AMENABLE GLA VARIANTS AND SEVERE RENAL IMPAIRMENT OR END-STAGE RENAL DISEASE TREATED WITH HEMODIALYSIS

This study looks at a capsule medicine called Galafold (migalastat) for adults with Fabry disease who have severe kidney problems or are on dialysis. Researchers want to see how the body absorbs and clears the medicine, and check if it is safe and properly dosed for damaged kidneys.